Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AmarinFRA:EH3 +1.65%58 EV-to-FCF is -0.76 as of Aug. 01, 2026. GuruFocus rates FRA:EH3 with a GF Score™ of 58/100 and a GF Value™ of €9.97 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 570 Drug Manufacturers companies, Amarin ranks better than 98.42% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Amarin's Enterprise Value is €-10.2 Mil.
Amarin's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €13.5 Mil. Therefore, Amarin's EV-to-FCF for today is -0.76.
The historical rank and industry rank for Amarin's EV-to-FCF or its related term are showing as below:
FRA:EH3'
s EV-to-FCF Range Over the Past 10 Years
Min: -743.65 Med: -8.96 Max: 204.12
Current: -0.61
During the past 13 years, the highest EV-to-FCF of Amarin was 204.12. The lowest was -743.65. And the median was -8.96.
FRA:EH3's EV-to-FCF is ranked better than 98.42% of 570
companies
in the Drug Manufacturers industry
Industry Median: 20.645
vs FRA:EH3: -0.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-01), Amarin's stock price is €12.30.
Amarin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.207. Therefore, Amarin's PE Ratio (TTM) for today is At Loss.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amarin's share price for today is €12.30.
Amarin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.207.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Amarin EV-to-FCF Related Terms
Amarin EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Amarin's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Amarin's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amarin EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amarin's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Amarin's EV-to-FCF falls into.
Amarin's current Enterprise Value is €-10.2 Mil.
Amarin's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amarin (FRA:EH3) has a EV-to-FCF of -0.76 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Amarin and its competitors. According to the industry distribution chart, Amarin ranks #9 out of 570 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is Amarin's EV-to-FCF too high?
Amarin's current EV-to-FCF is -0.76. Based on the distribution chart, Amarin ranks #9 out of 570 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amarin has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amarin's EV-to-FCF compare to SCLX and MIRA?
According to the Drug Manufacturers industry distribution chart, Amarin ranks #9 out of 570 companies for EV-to-FCF. This places Amarin in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.65, based on 570 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Amarin and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amarin's current EV-to-FCF is -0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amarin stock overvalued right now?
Based on GuruFocus' analysis, Amarin (FRA:EH3) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.97, compared to a current price of €12.30 — trading 23.4% above its estimated fair value. The current EV-to-FCF is -0.76. Amarin's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Amarin (FRA:EH3), the current EV-to-FCF is -0.76 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amarin (FRA:EH3) Overvalued in 2026?
Based on GuruFocus' analysis, Amarin stock appears to be overvalued.
The current stock price of €12.30 is trading 23.4% above its estimated GF Value™ of €9.97.
GuruFocus considers Amarin to be Modestly Overvalued.
Key valuation signals for FRA:EH3:
EV-to-FCF: -0.76
GF Value™: €9.97 vs. price of €12.30 (23.4% above fair value)
No single metric tells the full story. See the FRA:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
58GF Score
Get the complete analysis for FRA:EH3
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EH3 has been successfully added to your 
